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Abstract
Background: This study aimed to investigate prolactin related symptoms (PRS) in individuals with schizophrenia
during risperidone maintenance treatment for one year, as well as to identify the risk factors for PRS.
Methods: In a multicenter, randomized, controlled, longitudinal study, clinically stabilized schizophrenia patients
(N = 374) were randomized to a no-dose-reduction group (N = 129) and 4-week (N = 125) and 26-week (N = 120)
reduction groups, in which the original dose was followed by a 50 % reduction over 8 weeks and subsequently
maintained. PRS were assessed via a scale of prolactin related adverse events, which included 16 items: menstrual cycle,
menstrual period, menstrual volume, menstrual irregularities, amenorrhea, dysmenorrhea, postpartum lactation,
gynecomastia, breast tenderness, sexual dysfunction, decreased sexual desire, erectile dysfunction, ejaculatory
dysfunction, impotence, increased body hair, and acne. The occurrence of PRS was assessed at baseline and
monthly for six months, followed by every two months. A mixed model was used.
Results: PRS at baseline were reported in 18.4, 15.0, and 14.0 % of the 4-week, 26-week, and no-dose-reduction
groups, respectively. Female gender, younger age at onset, and the Positive and Negative Syndrome Scale (PANSS)
total scores at entry predicted the development of PRS. The mixed model indicated that PRS were more severe in
females and at a high dose. In the 237 patients who remained in the study after one year, the incidence of PRS
decreased to 9.6, 11.1, and 7.6 % in the 4-week, 26-week, and no-dose-reduction groups, respectively.
Conclusion: These findings indicate that the PRS severity was alleviated during the one year treatment period because
of the dose reduction. Attention should focus on the side effects of hyperprolactinemia during long-term treatment,
especially with a high dose, females, younger age at onset, and more severe patients.
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Background
Hyperprolactinemia is one of the most common
antipsychotic-induced adverse events in psychiatric pa-
tients [1], especially patients treated with first generation
antipsychotics or the second generation antipsychotics
risperidone or amisulpride [2–4]. In Chinese schizophre-
nia patients, the hyperprolactinemia rate was increased
in patients treated with risperidone compared with quetia-
pine, olanzapine, clozapine and aripiprazole [5, 6]. More-
over, the prevalence of hyperprolactinemia in females
treated with risperidone was greater than conventional
antipsychotic medications [7]. A substantial number of
studies have demonstrated that the treatment of schizo-
phrenia with risperidone may cause a substantial plasma
prolactin increase and an unacceptably high incidence of
prolactin related symptoms (PRS), such as amenorrhea,
galactorrhea, gynecomastia, and sexual dysfunction [8, 9].
PRS, including menstrual disturbances, amenorrhea,
galactorrhea, sexual dysfunction, gynecomastia, and im-
potence [10–12], may lead to clinical consequences,
such as infertility [9], decreased bone mineral density
and fracture risk [13, 14], metabolic syndrome [15], ex-
acerbation of autoimmune disorders [16], risks for cardio-
vascular disease [17], breast or prostate cancers [18, 19],
poor treatment adherence, and fluctuations in psychotic
symptoms [20]. These associated consequences may ser-
iously affect patient quality of life. Specifically, the treat-
ment of schizophrenia with risperidone may cause a
substantial prolactin increase and an unacceptably high
incidence of PRS, such as amenorrhea, galactorrhea,
gynecomastia, and sexual dysfunction [3, 8, 9]. Thus, in-
creased attention should focus on the PRS of risperidone,
which is widely used in schizophrenia treatment.
The risperidone maintenance treatment in schizophre-
nia (RMTS) study was designed to determine the dur-
ation of maintenance treatment required with the initial
therapeutic dose compared with a reduced dose over
time. The main results of the study were published in
2010 [21], and specific issues, such as sex differences
[22], cigarette smoking [22], weight changes [23], socio-
demographic and clinical profiles of paranoid and non-
paranoid schizophrenia [24], predictors of relapse [25],
and extrapyramidal symptoms [26], have been addressed
in subsequent papers. Regarding PRS, the initial analysis
analyzed the presence of prolactin-related adverse events
at 4 weeks and the end of the study, regardless of the
other time points.
This study aimed to investigate the PRS of risperidone
maintenance treatment in schizophrenia. The first ob-
jective was to investigate the baseline PRS associated
with risperidone and the socio-demographic and clinical
predictors. The second objective was to compare the tra-
jectory of PRS over time in different dose groups, as well
as identify potentially related factors.
Methods
Participants
Complete baseline data for PRS were available for 374
participants, which comprised 46 % males and 54 % fe-
males, with a mean age of 32.6 years (SD = 10.8). Pa-
tients were recruited from December 1, 2002 to January
31, 2005 at 19 mental health centers in China, which
represent a range of clinical settings.
The inclusion criteria were as follows: an age between
18 and 65 years; male or female; a diagnosis of DSM-IV
schizophrenia; clinical stability defined as <36 points on
the Brief Psychiatric Rating Scale (BPRS) [27] for at least
4 weeks but not more than 8 weeks following an acute
episode; monotherapy of risperidone at an optimal
therapeutic dose (4–8 mg/day) in the acute phase of
treatment and had responded to antipsychotic treatment;
satisfactory adherence defined by a pill count that
yielded more than 80 % adherence to the risperidone
prescription over the previous 4 weeks; and ability and
willingness to provide written informed consent. The ex-
clusion criteria included a history of or an ongoing
major chronic medical or neurological condition; a his-
tory of ECT or use of antidepressants, mood stabilizers,
or Chinese herbal remedies concomitantly with risperi-
done or previous participation in any other drug trial or
interventional study over the 4 weeks prior to study
entry; abuse of drugs or alcohol other than nicotine; and
pregnancy or plans to become pregnant, lactation, or
lack of an effective method of birth control.
Design
A computer-based central telephone randomization sys-
tem was used. The patients who met the inclusion cri-
teria were randomly assigned to three groups: the 4-
week group (initial optimal therapeutic dose continued
for 4 weeks, followed by a 50 % dose reduction over the
subsequent 8 weeks, which was then maintained until
the end of the study), the 26-week group (initial optimal
therapeutic dose continued for 26 weeks, followed by a
50 % dose reduction over 8 weeks until the end of the
study), and the no-dose-reduction group (initial optimal
therapeutic dose continued throughout the study). Dose
adjustments were not allowed prior to the dose reduc-
tion period. The study continued until the last recruited
patient completed his or her one-year follow-up. Pa-
tients were excluded from the study because of several
conditions: relapse, pregnancy, a severe medical condi-
tion, or newly emerging and intolerable side effects;
these patients were subsequently treated as clinically ap-
propriate. The study protocols were approved by the
clinical research ethics committees of the respective
study centers. Written informed consent was obtained
from each participant. The report of the study adheres
to the CONSORT guidelines.
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Assessments
Basic socio-demographic and clinical characteristics
were collected using a questionnaire designed for the
study. The BPRS was used as a screening tool at entry,
which was used to measure psychiatric symptoms. Re-
lapse was defined according to Csernansky’s criteria [28].
Psychopathology was evaluated using the Chinese ver-
sion of the PANSS [29]. PRS were assessed via a scale of
prolactin related adverse events, which included 16
items: menstrual cycle, menstrual period, menstrual vol-
ume, menstrual irregularities, amenorrhea, dysmenorrhea,
postpartum lactation, gynecomastia, breast tenderness,
sexual dysfunction, decreased sexual desire, erectile dys-
function, ejaculatory dysfunction, impotence, increased
body hair, and acne. For each item, 1 represents yes and 0
represents no symptom. The total score indicates the se-
verity of the PRS. These assessments were performed
monthly during the first six months, followed by every
two months until the last enrolled patient completed the
study, which included the end of the study or the time of
relapse, discontinuation, or dropout. All raters comprised
qualified psychiatrists who were trained to use the scales
prior to the start of the study.
Statistical analyses
All analyses were conducted with Statistics Analysis
System (SAS Institute, Inc., Cary, N.C., USA). At base-
line, PRS were described by a binary variable that
depended on the prolactin related adverse events. Specif-
ically, the patients were considered to have developed
PRS if one of the 16 items was positive (PRS group) at
baseline, whereas the remaining patients were considered
to have no PRS (No-PRS group). A stepwise logistic re-
gression analysis was used to adjust for relevant covariates
and to determine the independent risk factors for PRS.
The dependent variable comprised the development of
PRS, and the independent variables included age, sex, edu-
cation, age at onset, duration of illness, risperidone dose
at baseline, overall length of risperidone treatment in this
episode, length of risperidone treatment at the optimal
therapeutic dose, and the total PANSS score.
Comparisons between the groups regarding socio-
demographic and clinical characteristics were performed
with standard descriptive statistics: analyses of variance
(ANOVAs) or non-parametric tests, such as Mann-
Whitney U or Kruskal-Wallis tests, for continuous vari-
ables. Pearson’s correlations, Chi-square tests, or Fisher’s
exact tests were used for categorical variables. To iden-
tify the between-group differences, a Hochberg adjust-
ment for multiple comparisons was implemented [30].
To examine the evolution of PRS in the three study
groups, a mixed model was estimated, which included
fixed covariates for individual background variables,
baseline values, time expressed in weeks, the interaction
between study groups, and time. The PANSS scores and
risperidone dose were added to the model as time-
varying covariates. The model distribution of the re-
sponse variable was continuous with a total score of
PRS. All statistical tests were set at 0.05 two-tailed.
Results
Baseline PRS and related factors
Table 1 indicates the participants’ socio-demographic and
clinical characteristics. There were significantly more
Table 1 Demographics and baseline characteristics
Characteristics No-PRS group (N = 315) PRS group (N = 59) Statistics Total (N = 374)
Mean SD Mean SD F P Mean SD
Age 32.9 10.9 31.2 10.0 1.30 0.256 32.6 10.8
Education (years) 12.2 2.3 12.6 2.2 1.74 0.188 12.2 2.3
Age at onset 26.6 8.9 24.4 7.6 3.18 0.075 26.3 8.8
Duration of illness (years) 6.6 6.7 7.1 7.7 0.23 0.628 6.7 6.9
Risperidone dose at baseline (mg/d) 4.3 0.6 4.4 0.6 0.30 0.582 4.4 0.6
Total treatment in this episode (months) 5.3 5.1 5.2 4.3 0.04 0.850 5.3 5.0
Overall length of risperidone treatment in this episode (days) 83.5 54.1 90.2 59.7 0.74 0.389 84.5 55.0
Length of risperidone treatment at optimal therapeutic dose (days) 55.4 48.7 54.6 25.1 0.02 0.901 55.2 45.8
PANSS total score 39.1 9.5 42.8 10.0 7.66 0.006 39.5 9.6
N % N % χ2 P N %
Number of male participants 166 52.7 6 10.2 36.185 <0.001 172 46.0
Married 133 42.2 27 45.8 0.440 0.802 160 42.8
Family history of psychiatric disorder(s) 25 7.9 8 13.6 1.953 0.162 33 8.8
Unemployed 149 47.9 30 50.2 1.450 0.484 179 47.8
PANSS Positive and Negative Syndrome Scale, SD standard deviation
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males in the PRS group compared with the no-PRS group
(χ2 = 36.185, P < 0.001). Moreover, the PANSS total score
was significantly increased in the PRS group compared
with the NO-PRS group (F = 7.66, P = 0.006). There were
no significant differences between the groups regarding
age, marital status, education level, employment, resi-
dence, history of psychiatric disorder(s), age at onset, dur-
ation of illness, overall length of risperidone treatment in
this episode and at optimal therapeutic doses, or the ris-
peridone doses at baseline. In the stepwise logistic regres-
sion analyses, gender, age at onset, and PANSS total
scores at entry independently predicted the development
of PRS (Table 2).
PRS during one-year treatment
The incidences of PRS at baseline and during the 52-
week study duration are indicated in Fig. 1. PRS at
baseline occurred in 18.4, 15.0, and 14 % of the 4-week,
26-week, and no-dose-reduction groups, respectively.
The percentages of PRS for the patients who continued
treatment after one year were decreased to 9.6, 11.1, and
7.6 % for the 4-week, 26-week, and no-dose-reduction
groups, respectively.
The mixed model indicated there was significant vari-
ation in the PRS over time, which were relieved after
baseline in all groups (F = 6.28, P = 0.013). An analysis of
the course of PRS using the mixed procedure indicated
there was no significant variation in the three groups over
time (F = 0.17, P = 0.684). Risperidone dose as a time-
varying covariate was included in the model, and a lower
dose indicated less severe PRS (F = 18.84, P < 0.001).
When corrected for the risperidone dose, the effect of
time disappeared, which suggests that the variation in the
PRS over time was because of the risperidone dose. Gen-
der was entered in the model, and the PRS were more se-
vere in females (F = 42.88, P < 0.001).
Dose and medication adherence
Pill counts were used to measure treatment adherence;
the percentages of pills taken were 97, 92, and 95 % in
the 4-week, 26-week, and no-dose-reduction groups, re-
spectively. Thus, medication adherence was deemed ac-
ceptable, and changes in the risperidone dosage are
presented in Table 3.
Discussion
This study comprises the first investigation to use a
mixed model approach to analyze PRS and determine
the course of manifestation over the entire study period.
Several conclusions may be drawn from this prospective,
multicenter study in schizophrenia patients treated with
risperidone.
In this study, male or female, age at onset and PANSS
total scores were associated with PRS. Female sex was
associated with severity of PRS, which were positively
linked to the PANSS total scores and negatively corre-
lated with age at onset. Most previous studies have been
conducted on hyperprolactinemia risk factors. The re-
sults of a number of studies have suggested that higher
antipsychotic doses, a longer duration of treatment, fe-
male sex, younger age, stress, and combination treat-
ment with an antidepressant comprised risk factors for
hyperprolactinemia [15, 20]. In a multiple logistic regres-
sion, younger age was an independent risk factor of
Table 2 Independent predictors of prolactin related symptoms
(logistic regression model)
Wald Chi-square P-value Odds ratio
estimates
95 % C.I.
Gender 31.3 <0.001 13.609 5.452–33.970
Age at onset 5.2 0.022 0.959 0.925–0.994
PANSS total scores 11.4 0.001 1.053 1.022–1.086
PANSS Positive and Negative Syndrome Scale, C.I. confidence interval
Fig. 1 Prevalence of PRS in patients who remained in treatment
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hyperprolactinemia [6]. Several studies have also demon-
strated that the risk of hyperprolactinemia decreased
with age [6, 31]. We did not identify an association be-
tween PRS and age; however, a negative association was
identified between PRS and age at onset. Similarly, it has
been demonstrated that the mean plasma prolactin level
was increased in early-onset schizophrenia spectrum
psychosis patients compared with no-early-onset pa-
tients [32]. Another finding of this study is that the ris-
peridone dose was positively associated with the severity
of PRS, which is consistent with the previous study. Fur-
thermore, it has been suggested that a dose-response re-
lationship is uncertain [33]. Previous evidence indicates
there was no correlation between the risperidone dose
and the incidence of side effects presumed to be caused
by hyperprolactinemia in patients [34]. Risperidone dose
may be more related to PRS than hormones. However,
few studies have investigated the relationship between
PRS and the PANSS scores. In a Korean study, the pro-
lactin levels in acute psychiatric inpatients who received
risperidone were not significantly correlated with im-
provements in the total BPRS scores [35].
As the treatment duration increased, the prevalence of
PRS decreased, even in the dose-reduction groups,
which may be attributed to the tolerability of the drug,
as well as the dropouts. However, the dose-reduction
strategies did not have a significant influence on the de-
scending trend in PRS occurrence, even at a low dose,
and the PRS remained similar to the relatively high dose.
This finding was supported by a review in which the au-
thors concluded that following long term administration
of antipsychotics, such as risperidone, tolerance and de-
creases in the prolactin level may occur [4].
Several limitations should be considered in the inter-
pretation of these results. One limitation is that the pa-
tients and clinicians were not blind to the treatment
group. Thus, bias as a result of expectation is a possibil-
ity that cannot be ruled out. Another limitation is that
we only reassessed the PRS of patients who continued
treatment in the study. This approach was implemented
because intolerable side effects, relapse, and other rea-
sons resulted in the discontinuation of treatment in a
proportion of the patients. Moreover, we used a binary
variable that was somewhat limited to describe PRS,
which does not reflect the severity of PRS. Finally, we
only assessed the PRS; we did not measure the plasma
prolactin level or other hormones with potential interac-
tions. The assessment of patients only based on symp-
toms related to increased plasma prolactin levels is not
ideal. Thus, further research is required to clarify this
complex situation to assess the potential correlations be-
tween abnormal laboratory values and the clinical mani-
festations of hyperprolactinemia.
Conclusions
In summary, the PRS severity was alleviated during the
one year treatment period because of the dose reduction.
Attention should focus on the side effects of hyperpro-
lactinemia during long-term treatment, especially with a
high dose, females, younger age at onset, and more se-
vere patients, because hyperprolactinemia related side
effects may comprise important concerns in patients
undergoing chronic therapy. Furthermore, a mixed
model approach may be implemented to assess PRS in
longitudinal studies with multiple time points.
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